CIK 0001833214 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SAB Biotherapeutics, Inc.
Sign in to watch- Ticker
- SABS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 853899721
- Phone
- 305-845-2813
- Business address
- 777 W 41ST ST, SUITE 401, MIAMI BEACH, FL, 33140
- Former names
- Big Cypress Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 16 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-07 | Sullivan Eddie Joe Chief Executive Officer | Purchase | +1,740 | $0.88 | $2K | 5,232,304 |
| 2023-11-30 | King Michael CHIEF FINANCIAL OFFICER | Purchase | +5,000 | $0.90 | $5K | 5,000 |
| 2023-11-29 | Reich Samuel J Executive Chairman | Purchase | +11,000 | $0.89 | $10K | 219,001 |
| 2023-11-24 | Sessa Capital (Master), L.P. Director | Option exercise | +4,584,571 | 4,584,571 | ||
| 2023-11-24 | Sessa Capital (Master), L.P. Director | Option exercise · Series A-1 Convertible Preferred Stock | −31,269 | $1,000.00 | $31.3M | 0 |
| 2023-11-24 | Sessa Capital (Master), L.P. Director | Option exercise · Series A-2 Convertible Preferred Stock | +28,380 | $1,000.00 | $28.4M | 28,380 |
| 2023-11-24 | Moin Andrew Director | Option exercise | +4,584,571 | 4,584,571 | ||
| 2023-11-24 | Moin Andrew Director | Option exercise · Series A-1 Convertible Preferred Stock | −31,269 | $1,000.00 | $31.3M | 0 |
| 2023-11-24 | Moin Andrew Director | Option exercise · Series A-2 Convertible Preferred Stock | +28,380 | $1,000.00 | $28.4M | 28,380 |
| 2023-11-24 | Ellias Helen K. Director | Option exercise | +2,857,142 | 2,857,142 | ||
| 2023-11-24 | Ellias Helen K. Director | Option exercise · Series A-1 Convertible Preferred Stock | −1,800 | $1,000.00 | $1.8M | 0 |
| 2023-11-13 | Sessa Capital (Master), L.P. Director | Grant or award · Series A-1 Convertible Preferred Stock | +13,269 | $1,000.00 | $13.3M | 31,269 |
| 2023-11-13 | Moin Andrew Director | Grant or award · Series A-1 Convertible Preferred Stock | +13,269 | $1,000.00 | $13.3M | 31,269 |
| 2023-11-13 | Sessa Capital (Master), L.P. Director | Option exercise · Tranche A Warrants | −13,269 | 0 | ||
| 2023-11-13 | Sessa Capital (Master), L.P. Director | Grant or award · Series A-1 Convertible Preferred Stock | +13,269 | $1,000.00 | $13.3M | 31,269 |
| 2023-11-13 | Moin Andrew Director | Option exercise · Preferred Tranche A Warrants | −13,269 | 0 | ||
| 2023-11-13 | Moin Andrew Director | Grant or award · Series A-1 Convertible Preferred Stock | +13,269 | $1,000.00 | $13.3M | 13,269 |
| 2023-11-10 | Sessa Capital (Master), L.P. Director | Grant or award · Tranche A Warrants | +13,269 | 13,269 | ||
| 2023-11-10 | Sessa Capital (Master), L.P. Director | Grant or award · Tranche B Warrants | +8,846 | 20,846 | ||
| 2023-11-10 | Sessa Capital (Master), L.P. Director | Grant or award · Tranche C Warrants | +22,115 | 52,115 |
Page 4 of 9 · 172 trades